H.C. Wainwright analyst Edward White maintained a Buy rating on Chemocentryx Inc. on Monday, setting a price target of $28, which is approximately 53.85% above the present share price of $18.2.
White expects Chemocentryx Inc. to post earnings per share (EPS) of -$0.56 for the third quarter of 2021.
The current consensus among 6 TipRanks analysts is for a Moderate Buy rating of shares in ChemoCentryx (NASDAQ:CCXI), with an average price target of $24.33.
The analysts price targets range from a high of $31 to a low of $14.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $1.7 million and a net profit of -$38.74 million. The company's market cap is $1.27 billion.
According to TipRanks.com, H.C. Wainwright analyst Edward White is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 29.7% and a 45.71% success rate.
ChemoCentryx, Inc. is a biopharmaceutical company engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in Mountain View, CA.